Skip to main content

Table 1 Model input parameters

From: Five-year cost-effectiveness analysis of the European Fans in Training (EuroFIT) physical activity intervention for men versus no intervention

PARAMETERS FOR THE BASE CASE ANALYSIS
  Values* Distribution for probabilistic sensitivity analysis Source
Physical activity (transition probabilities at the end of each cycle of 12 months)
EuroFIT
 Inactive to Inactive 0.18 Beta (α = 4.0, β = 17.0) EuroFIT RCT [20]
 Inactive to Moderately active 0.054 Beta (α = 0.34, β = 5.7) EuroFIT RCT [20]
 Inactive to Recommended activity 0.71 Beta (α = 59.4, β = 19.6) EuroFIT RCT [20]
 Moderately active to Moderately active 0.042 Beta (α = 0.09, β = 1.9) EuroFIT RCT [20]
 Moderately active to Inactive 0.085 Beta (α = 0.44, β = 4.56) EuroFIT RCT [20]
 Moderately active to Recommended activity 0.82 Beta (α = 33.8, β = 5.2) EuroFIT RCT [20]
 Recommended activity to Recommended Activity 0.89 Beta (α = 357.9, β = 26.1) EuroFIT RCT [20]
 Recommended activity to Inactive 0.042 Beta (α = 0.83, β = 18.2) EuroFIT RCT [20]
 Recommended activity to Moderately active 0.023 Beta (α = 0.24, β = 9.8) EuroFIT RCT [20]
No intervention
 Inactive to Inactive 0.33 Beta (α = 11.5, β = 21.5) EuroFIT RCT [20]
 Inactive to Moderately active 0.12 Beta (α = 1.6, β = 10.4) EuroFIT RCT [20]
 Inactive to Recommended activity 0.49 Beta (α = 25.0, β = 23.0) EuroFIT RCT [20]
 Moderately active to Moderately active 0.17 Beta (α = 1.5, β = 6.6) EuroFIT RCT [20]
 Moderately active to Inactive 0.19 Beta (α = 2.1, β = 8.0) EuroFIT RCT [20]
 Moderately active to Recommended activity 0.58 Beta (α = 16.6, β = 10.4) EuroFIT RCT [20]
 Recommended activity to Recommended Activity 0.80 Beta (α = 290.7, β = 58.3) EuroFIT RCT [20]
 Recommended activity to Inactive 0.10 Beta (α = 4.2, β = 37.8) EuroFIT RCT [20]
 Recommended activity to Moderately active 0.064 Beta (α = 1.9, β = 26.1) EuroFIT RCT [20]
Health conditions (transition probabilities at the end of each cycle of 12 months)
 Inactive to colorectal cancer 0.015 Fixed COSM study [30, 31]
 Inactive to heart diseases 0.011 Fixed Meta-analysis; SALLS study [30, 32,33,34]
 Inactive to Type 2 diabetes 0.005 Fixed EPIC-Interact study and epidemiological study [33, 35, 36]
 Inactive to stroke 0.0046 Fixed ARIC study [37]
 Inactive to depression 0.010 Fixed Meta-analysis; Health survey for England and Scotland [34, 35, 38]
 Moderately active to colorectal cancer 0.011 Fixed COSM study [30, 31]
 Moderately active to heart disease 0.009 Fixed Meta-analysis; SALLS study [30, 32,33,34]
 Moderately active to Type 2 diabetes 0.0038 Fixed EPIC-Interact study; epidemiological study [33, 35, 36]
 Moderately active to stroke 0.0033 Fixed ARIC study [37]
 Moderately active to depression 0.0094 Fixed Meta-analysis; Health survey for England and Scotland [34, 35, 38]
 Recommended activity to colorectal cancer 0.0096 Fixed COSM study [30, 31]
 Recommended activity to heart disease 0.008 Fixed Meta-analysis; SALLS study [30, 32,33,34]
 Recommended activity to Type 2 diabetes 0.0033 Fixed EPIC-Interact study; epidemiological study [33, 35, 36]
 Recommended activity to stroke 0.0029 Fixed ARIC study [37]
 Recommended activity to depression 0.0092 Fixed Meta-analysis; Health survey for England and Scotland [34, 38, 39]
Mortality (transition probabilities at the end of each cycle of 12 months)
 Inactive to death 0.016 Fixed Meta-analysis; epidemiological study [73, 74, 75, 76]
 Moderately active to death 0.012 Fixed Meta-analysis; epidemiological study [73, 74, 75, 76]
 Recommended activity to death 0.010 Fixed Meta-analysis; epidemiological study [73, 74, 75, 76]
 Colorectal cancer to death 0.092 Fixed International Cancer Benchmarking partnership registries [40]
 Coronary heart disease to death 0.002 Fixed WONDER registry [41]
 Type 2 diabetes to death 0.015 Fixed ZODIAC study [42]
 Stroke to death 0.400 Fixed MONICA registry [43]
 Depression to death 0.030 Fixed STIRLING registry [44]
Utility values
 Inactive – Base case 0.909 Beta (α = 3.0, β = 0.38) EuroFIT RCT [20]
 Moderately active – Base case 0.919 Beta (α = 5.1, β = 0.51) EuroFIT RCT [20]
 Recommended activity – Base case 0.922 Beta (α = 5.1, β = 0.43) EuroFIT RCT [20]
 Colorectal cancer 0.786 Fixed Systematic review [45]
 Coronary hearth disease 0.735 Fixed Longitudinal survey [46]
 Stroke 0.62 Fixed Longitudinal survey [47]
 Type 2 diabetes 0.785 Fixed Systematic review [48]
 Depression 0.57 Fixed Systematic review [49]
Annual costs per person according to the societal perspective (€ 2017)
 Inactive 2436 Gamma (shape = 0.19, scale = 12,658) EuroFIT RCT [20]
 Moderately active 1506 Gamma (shape = 0.22, scale = 6920) EuroFIT RCT [20]
 Recommended activity 1997 Gamma (shape = 0.24, scale = 8222) EuroFIT RCT [20]
 Colorectal cancer 34,085 Fixed Cross sectional study; Health insurance registry [50, 51]
 Coronary heart disease 5239 Fixed Economic burden [52]
 Type 2 diabetes 5907 Fixed Economic burden [53]
Stroke 24,979 Fixed Economic burden [54]
 Depression 6819 Fixed Cost-effectiveness analysis [55]
 EuroFIT program 260 Fixed EuroFIT RCT [20]
PARAMETERS FOR THE SENSITIVITY ANALYSES
Utility values
 Inactive – Literature utilities 0.80 Fixed Economic evaluation [24]
 Moderately active – Literature utilities 0.87 Fixed Economic evaluation [24]
 Recommended activity – Literature utilities 0.91 Fixed Economic evaluation [24]
Annual costs per person according to the healthcare perspective (€ 2017)
 Inactive 1107 Gamma (shape = 0.10, scale = 10,924) EuroFIT RCT [20]
 Moderately active 594 Gamma (shape = 0.35, scale = 1707) EuroFIT RCT [20]
 Recommended activity 747 Gamma (shape = 0.19, scale = 4040) EuroFIT RCT [20]
 Colorectal cancer 25,346 Fixed Cross sectional study; Health insurance registry [50, 51]
 Coronary heart disease 1954 Fixed Economic burden [52]
 Type 2 diabetes 3089 Fixed Economic burden [53]
 Stroke 18,750 Fixed Economic burden [54]
 Depression 966 Fixed Cost-effectiveness analysis [55]
  1. *Values represent probabilities, mean utilities or mean costs
Back to article page

International Journal of Behavioral Nutrition and Physical Activity

ISSN: 1479-5868

Contact us